Please assess the completion status of the following clinical trial:

Trial Title: The Safety and Efficacy of SPD465 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult men and non-pregnant women between the ages of 18 and 55~* Confirmed diagnosis of ADHD as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)~* Baseline ADHD score of at least 24~Exclusion Criteria:~* Weight less than 100 pounds or greater than 250 pounds~* Psychiatric diagnosis such as a severe comorbid Axis II or Axis I disorder~* Pregnancy or breastfeeding~* History of seizures~* Positive urine drug screen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- SPD465 (50 or 75 mg) (Type: EXPERIMENTAL): None
- Immediate Release Amphetamine salt (25 mg) (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).